MYF-616小方坯连铸机存在的问题及改造

对MYF-616小方坯连铸机系统在生产运行中存在的问题,进行了分析,提出了相应的解决方案,取得了显著的经济效益.     

液膜技术在医药化工中的应用

液膜分离技术是一种新兴的技术,它是利用混合物各组分渗透性能的差异来实现分离、提纯或浓缩的。介绍了液膜技术的原理及其特点和此技术在生化、医药化工领域的应用,据此提出了液膜技术未来研究的重点及应用途径。     

考虑垫底气回收价值及资金时间价值的盐穴型地下储气库储气费计算方法

我国的地下储气库(以下简称储气库)与油气管道捆绑运营,没有单独的定价机制,计算储气库储气费时也未充分考虑资金的时间价值及油气藏型、盐穴型储气库垫底气的回收价值,导致计算结果的准确性欠佳。未来储气库实行独立、市场化运营是必然趋势,因而需要建立一种符合我国储气库运营模式的储气费定价机制。为此,以国内某盐穴型储气库建设投资项目为例,采用二分法建立了一种考虑垫底气可回收的储气费计算模型,计算出该储气库在不同内部收益率下的储气费,并分析了影响储气费的主要因素。结果表明:(1)当储气费为1.02元/m~3时,可满足内部收益率8%的要求;(2)在盐穴储气库工作气量确定的情况下,年储转次数(储气库年实际注采气量与年设计工作气量的比值)是影响储气费的最重要因素,地下及地面工程等建设投资的影响次之,而经营成本的影响最小;(3)在储转次数大于1.4时,盐穴储气库注采运行的工作效率达到最大,建议将盐穴储气库的储转次数设定为1.4。结论认为:该储气费计算方法在保证能获得一定利润的前提下,充分考虑了资金的时间价值以及垫底气的回收价值,计算得到的储气费较为合理,可推广到类似盐穴型储气库的应用计算。     

恩诺沙星注射液在猪体内残留消除规律研究

目的研究恩诺沙星注射液在猪体内的残留消除规律。方法本实验采用30头约50 kg重长白猪,随机分为2组,给药组25头,对照组5头。给药组用药量为每次2.5mg恩诺沙星/kg,每日1次,连用3d(1个疗程),使用1个疗程,对照组不给任何抗菌药物,与给药组同环境饲养。在最后一次给药6 h、24 h(1 d)、72 h(3 d)、120 h(5 d)、168 h(7 d)时采集肉、肝、肾、脂肪样本,经液相色谱-串联质谱法(liquid chromatography-tandem mass spectrometry, LC-MS/MS)测定组织中的恩诺沙星及其代谢物环丙沙星残留量之和,并利用WT1.4软件计算休药期。结果恩诺沙星注射液在猪肉中的休药期为3.17 d;在肾脏中的休药期为3.75 d;在肝脏中的休药期为8.18 d;在脂肪总的休药期为4.09 d。结论为保证兽药使用安全、食品安全和消费者健康,推荐恩诺沙星注射液在猪体内的休药期为9 d。     

Evaluation of tetracycline in milk following extra-label administration of topical tetracycline for digital dermatitis in dairy cattle

Digital dermatitis (DD) is a painful infectious foot lesion commonly treated topically with extra-label tetracycline. Our objectives were to determine the concentrations of tetracycline in milk and plasma and to calculate a withdrawal interval following topical application at various doses. Another objective was to evaluate agreement between tests for measuring tetracycline in milk. A randomized block trial was conducted on 2 farms, where 50 cows with active DD lesions on 2 feet were allocated to 1 of 5 treatment groups (n = 10 cows per group). Treatment groups consisted of topical applications of tetracycline hydrochloride, in a paste or as a powdered form under a bandage, at 3 different dosing levels (2, 5, and 25 g) on each of the 2 affected feet. Following enrollment and treatment, samples were collected from milk, teat skin, and blood every 8 to 24 h for up to 7 d postdosing. Concentrations of tetracycline were measured by liquid chromatography-mass spectrometry and milk samples were further tested using the Charm ROSA TET test (Charm Sciences Inc., Lawrence, MA). Tetracycline was present in milk, plasma, and teat skin from all treatment groups. Tetracycline concentrations varied depending on time of sampling, method of application, and dosing level. At 8 h post-treatment, 11% of cows had tetracycline present in milk higher than 100 ng/mL (ppb) but none higher than 300 ng/mL. The 25-g treatment group had the longest estimated withdrawal interval, the highest observed concentrations (210–244 ng/mL) of tetracycline present in milk, and the longest observed consecutive period of tetracycline presence (from 8 to 72 h) among all treatment groups. Compared with liquid chromatography-mass spectrometry, the Charm test had a sensitivity of 77 and 100% for measuring tetracycline in milk at ≥30 and ≥100 ng/mL, respectively. Post-treatment samples of the teat skin were taken from 15 cows on 6 occasions, and every cow had tetracycline present in at least 1 of those 6 samples. This confirms an association between topical DD treatment with tetracycline and contamination of the teat. A total of 22% of blood samples had detectable tetracycline, and the majority (63%) occurred at 8 h post-treatment. At 100 ng/mL, the estimated cow-level milk withdrawal interval ranged from 0 to 70 h. At 300 ng/mL, the estimated cow-level withdrawal interval ranged from 0 to 34 h, and was 0 h at the bulk tank level. We recommend that conservative measures be adopted after extra-label use of topical tetracycline for DD treatment, including using a low dose and strategic post-treatment testing for tetracycline-class drugs in milk.     

皮肤T细胞淋巴瘤局部用药和物理治疗的研究进展

皮肤T细胞淋巴瘤(cutaneous T cell lymphoma,CTCL)大多属于惰性淋巴瘤,病情进展缓慢,患者确诊时多处于疾病早期。局部用药和物理治疗在CTCL治疗中占重要地位,包括局部外用皮质类固醇激素、免疫抑制剂、维A酸,放疗及光疗等。近年来,有研究对CTCL传统局部用药和物理治疗方法的有效性和安全性进行了重新评估。同时,新型CTCL局部用药和物理治疗策略也不断涌现,如局部外用他扎罗汀、瑞喹莫特,紫外线A联合新型光敏剂的光化学疗法和光动力治疗等。本文对CTCL局部用药和物理治疗的研究进展作一综述。     

Towards patient‐centered packaging design: An industry perspective on processes,functions, and constraints

Medication packaging is essential to provide patients with guidance and correct use of their medicines for effective treatment. This research aims to increase knowledge about the medication packaging innovation process and its uptake towards patient‐centered packaging design. The study applied a qualitative research approach based on data from 25 in‐depth interviews with stakeholders involved in medication packaging design. The empirical data analysis revealed four themes that can improve and advance user‐centered packaging design: medication packaging innovation process, medication packaging functions and features, medication packaging design constraints, and patient‐centered medication packaging design. The findings suggest that medication packaging design is strongly affected by an emphasis on protective and safety packaging functions rather than on patients' needs. Packaging innovation usually is constrained by rigid incremental development processes, where compliance with regulations, extensive documentation, avoidance of manufacturing complexity, and considerations on cost prevail. These findings are discussed in relation to the three most evident trade‐offs for patient‐centered design: protection versus openability, utility versus cost, and complexity of manufacturability versus complexity of use. This research contributes with valuable input and additional evidence about the necessary shift to a user‐centered approach in a field that has not been design driven. This input complements previous research and provides an opportunity for industry decision makers and policy makers to lead patient‐centered packaging design that can benefit patients and relieve overloaded health care systems.     

延河泉水源地水资源评价

依据延河泉泉域和泉区水文地质条件,计算延河泉流量,并建立二维泉域数学模型,计算上游水源地开采后对延河泉流量的削减值,从而评价延河泉的B级允许开采量。